10x Genomics Key Executives
This section highlights 10x Genomics's key executives, including their titles and compensation details.
Find Contacts at 10x Genomics
(Showing 0 of )
10x Genomics Earnings
This section highlights 10x Genomics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-12 | $-0.29 | $-0.40 |
| Read Transcript | Q3 | 2024 | 2024-10-29 | $-0.34 | $-0.30 |
| Read Transcript | Q2 | 2024 | 2024-08-08 | $-0.47 | $-0.32 |
| Read Transcript | Q1 | 2024 | 2024-04-30 | $-0.46 | $-0.50 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | $-0.36 | $-0.41 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $-0.45 | $-0.51 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $-0.39 | $-0.53 |
| Read Transcript | Q1 | 2023 | 2023-05-03 | $-0.38 | $-0.44 |
Financial Statements
Access annual & quarterly financial statements for 10x Genomics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $610.78M | $618.73M | $516.41M | $490.49M | $298.85M |
| Cost of Revenue | $196.30M | $209.41M | $120.39M | $74.09M | $58.47M |
| Gross Profit | $414.48M | $409.31M | $396.02M | $416.40M | $240.38M |
| Gross Profit Ratio | 67.86% | 66.15% | 76.69% | 84.89% | 80.44% |
| Research and Development Expenses | $264.70M | $270.33M | $265.67M | $211.75M | $123.38M |
| General and Administrative Expenses | $- | $340.03M | $294.60M | $252.86M | $200.43M |
| Selling and Marketing Expenses | $- | $3.30M | $3.70M | $4.70M | $1.90M |
| Selling General and Administrative Expenses | $344.34M | $343.33M | $298.30M | $257.56M | $202.33M |
| Other Expenses | $- | $- | $-198.00K | $-802.00K | $1.34M |
| Operating Expenses | $609.04M | $674.95M | $563.97M | $469.31M | $325.70M |
| Cost and Expenses | $805.34M | $884.36M | $684.35M | $543.40M | $384.17M |
| Interest Income | $18.45M | $16.91M | $6.65M | $206.00K | $1.53M |
| Interest Expense | $4.00K | $33.00K | $476.00K | $866.00K | $1.68M |
| Depreciation and Amortization | $43.71M | $43.62M | $33.01M | $28.25M | $19.02M |
| EBITDA | $-133.99M | $-205.11M | $-128.49M | $-24.59M | $-513.77M |
| EBITDA Ratio | -21.94% | -33.15% | -24.88% | -5.01% | -171.92% |
| Operating Income | $-194.56M | $-194.95M | $-167.94M | $-52.91M | $-85.32M |
| Operating Income Ratio | -31.85% | -31.51% | -32.52% | -10.79% | -28.55% |
| Total Other Income Expenses Net | $16.86M | $-53.81M | $5.97M | $-802.00K | $-449.15M |
| Income Before Tax | $-177.70M | $-248.76M | $-161.97M | $-53.72M | $-534.48M |
| Income Before Tax Ratio | -29.09% | -40.21% | -31.36% | -10.95% | -178.85% |
| Income Tax Expense | $4.93M | $6.34M | $4.03M | $4.51M | $8.26M |
| Net Income | $-182.63M | $-255.10M | $-166.00M | $-58.22M | $-542.73M |
| Net Income Ratio | -29.90% | -41.23% | -32.15% | -11.87% | -181.61% |
| EPS | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 |
| EPS Diluted | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 |
| Weighted Average Shares Outstanding | 120.45M | 117.17M | 113.86M | 110.35M | 101.15M |
| Weighted Average Shares Outstanding Diluted | 120.45M | 117.17M | 113.86M | 110.35M | 101.15M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $165.02M | $151.65M | $153.10M | $141.01M | $183.98M | $153.64M | $146.82M | $134.28M | $156.23M | $131.07M | $114.61M | $114.50M | $143.53M | $125.30M | $115.84M | $105.82M | $112.22M | $71.82M | $42.91M | $71.91M |
| Cost of Revenue | $54.07M | $45.26M | $46.21M | $45.44M | $77.91M | $58.12M | $47.21M | $35.90M | $36.83M | $30.38M | $27.70M | $25.48M | $27.60M | $24.52M | $4.92M | $17.06M | $18.90M | $14.41M | $10.05M | $15.11M |
| Gross Profit | $110.95M | $106.39M | $106.90M | $95.57M | $106.06M | $95.53M | $99.61M | $98.39M | $119.41M | $100.69M | $86.91M | $89.02M | $115.93M | $100.78M | $110.93M | $88.76M | $93.32M | $57.41M | $32.85M | $56.80M |
| Gross Profit Ratio | 67.24% | 70.16% | 69.82% | 67.78% | 57.65% | 62.18% | 67.85% | 73.27% | 76.43% | 76.82% | 75.83% | 77.75% | 80.77% | 80.43% | 95.76% | 83.88% | 83.16% | 79.93% | 76.57% | 78.99% |
| Research and Development Expenses | $66.97M | $66.17M | $62.92M | $67.94M | $55.55M | $107.91M | $71.46M | $67.10M | $63.61M | $67.29M | $70.69M | $64.08M | $61.88M | $54.58M | $53.40M | $41.88M | $39.70M | $30.14M | $27.54M | $25.99M |
| General and Administrative Expenses | $- | $- | $- | $- | $82.83M | $- | $- | $- | $75.19M | $- | $- | $- | $65.18M | $- | $- | $- | $54.07M | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $3.30M | $- | $- | $- | $3.70M | $- | $- | $- | $4.70M | $- | $- | $- | $1.90M | $- | $- | $- |
| Selling General and Administrative Expenses | $93.83M | $81.70M | $83.04M | $84.67M | $86.12M | $82.42M | $91.51M | $83.28M | $78.89M | $73.40M | $79.34M | $66.67M | $69.88M | $62.08M | $68.70M | $56.90M | $55.97M | $51.55M | $44.42M | $50.39M |
| Other Expenses | $- | $- | $-2.68M | $-2.35M | $3.96M | $-1.25M | $-1.50M | $-1.52M | $4.00M | $-1.95M | $-1.84M | $-400.00K | $5.00K | $-599.00K | $521.00K | $-729.00K | $1.22M | $361.00K | $-144.00K | $-96.00K |
| Operating Expenses | $160.79M | $147.88M | $148.63M | $154.97M | $141.68M | $190.32M | $162.97M | $150.38M | $142.50M | $140.69M | $150.02M | $130.75M | $131.76M | $116.66M | $122.11M | $98.79M | $95.68M | $81.69M | $71.95M | $76.38M |
| Cost and Expenses | $214.86M | $193.14M | $194.84M | $200.40M | $219.59M | $248.44M | $210.18M | $186.27M | $179.33M | $171.07M | $177.73M | $156.23M | $159.36M | $141.18M | $127.02M | $115.85M | $114.58M | $96.10M | $82.00M | $91.49M |
| Interest Income | $4.03M | $4.97M | $4.71M | $4.74M | $4.64M | $4.30M | $4.10M | $3.87M | $2.81M | $2.02M | $1.24M | $569.00K | $49.00K | $49.00K | $58.00K | $50.00K | $61.00K | $28.00K | $125.00K | $1.32M |
| Interest Expense | $- | $2.00K | $1.00K | $1.00K | $8.00K | $1.00K | $5.00K | $19.00K | $125.00K | $114.00K | $109.00K | $128.00K | $217.00K | $219.00K | $209.00K | $221.00K | $317.00K | $397.00K | $306.00K | $662.00K |
| Depreciation and Amortization | $10.56M | $10.75M | $10.90M | $11.49M | $11.71M | $11.42M | $11.88M | $8.62M | $8.47M | $8.12M | $8.44M | $7.97M | $7.32M | $7.28M | $7.19M | $6.47M | $5.42M | $4.88M | $4.47M | $4.26M |
| EBITDA | $-37.82M | $-23.69M | $-26.18M | $-46.31M | $-34.88M | $-80.32M | $-48.88M | $-41.02M | $-7.81M | $-31.81M | $-55.28M | $-33.59M | $-8.45M | $-9.15M | $-2.56M | $-4.43M | $-402.89M | $-59.99M | $-34.97M | $-16.99M |
| EBITDA Ratio | -22.92% | -15.62% | -17.10% | -32.84% | -18.96% | -52.28% | -33.30% | -30.55% | -5.00% | -24.27% | -48.23% | -29.34% | -5.89% | -7.31% | -2.21% | -4.18% | -359.02% | -83.53% | -81.51% | -23.63% |
| Operating Income | $-49.84M | $-41.48M | $-41.74M | $-59.40M | $-35.61M | $-94.80M | $-63.36M | $-51.99M | $-23.10M | $-40.00M | $-63.12M | $-41.73M | $-15.83M | $-15.88M | $-10.33M | $-10.22M | $-409.58M | $-65.25M | $-39.42M | $-19.88M |
| Operating Income Ratio | -30.20% | -27.36% | -27.26% | -42.12% | -19.36% | -61.70% | -43.15% | -38.71% | -14.78% | -30.51% | -55.07% | -36.45% | -11.03% | -12.67% | -8.92% | -9.65% | -364.99% | -90.86% | -91.88% | -27.65% |
| Total Other Income Expenses Net | $1.46M | $7.05M | $4.66M | $1.59M | $-10.99M | $3.05M | $2.59M | $2.33M | $6.68M | $-39.00K | $-714.00K | $41.00K | $-163.00K | $-769.00K | $370.00K | $-900.00K | $960.00K | $-8.00K | $-325.00K | $-961.00K |
| Income Before Tax | $-48.38M | $-34.44M | $-37.08M | $-57.80M | $-46.60M | $-91.74M | $-60.77M | $-49.65M | $-16.41M | $-40.03M | $-63.83M | $-41.69M | $-15.99M | $-16.65M | $-9.96M | $-11.12M | $-408.62M | $-65.26M | $-39.74M | $-20.84M |
| Income Before Tax Ratio | -29.32% | -22.71% | -24.22% | -40.99% | -25.33% | -59.71% | -41.39% | -36.98% | -10.50% | -30.54% | -55.69% | -36.42% | -11.14% | -13.29% | -8.60% | -10.50% | -364.13% | -90.87% | -92.63% | -28.99% |
| Income Tax Expense | $648.00K | $1.31M | $818.00K | $2.15M | $2.35M | $1.24M | $1.65M | $1.09M | $804.00K | $1.88M | $627.00K | $719.00K | $2.46M | $523.00K | $1.09M | $435.00K | $6.95M | $585.00K | $422.00K | $298.00K |
| Net Income | $-49.03M | $-35.75M | $-37.90M | $-59.95M | $-48.95M | $-92.99M | $-62.41M | $-50.75M | $-17.21M | $-41.91M | $-64.46M | $-42.41M | $-18.45M | $-17.17M | $-11.05M | $-11.55M | $-415.57M | $-65.85M | $-40.17M | $-21.14M |
| Net Income Ratio | -29.71% | -23.58% | -24.75% | -42.52% | -26.61% | -60.52% | -42.51% | -37.79% | -11.02% | -31.98% | -56.24% | -37.04% | -12.85% | -13.70% | -9.54% | -10.92% | -370.33% | -91.69% | -93.62% | -29.40% |
| EPS | $-0.41 | $-0.30 | $-0.32 | $-0.50 | $-0.41 | $-0.79 | $-0.53 | $-0.44 | $-0.15 | $-0.37 | $-0.57 | $-0.38 | $-0.16 | $-0.15 | $-0.10 | $-0.11 | $-3.87 | $-0.65 | $-0.41 | $-0.22 |
| EPS Diluted | $-0.41 | $-0.30 | $-0.32 | $-0.50 | $-0.41 | $-0.79 | $-0.53 | $-0.44 | $-0.15 | $-0.37 | $-0.57 | $-0.38 | $-0.16 | $-0.15 | $-0.10 | $-0.11 | $-3.87 | $-0.65 | $-0.41 | $-0.22 |
| Weighted Average Shares Outstanding | 120.45M | 120.73M | 120.07M | 119.39M | 118.57M | 117.73M | 116.71M | 115.62M | 114.76M | 114.11M | 113.57M | 112.97M | 111.90M | 110.87M | 109.87M | 108.71M | 107.27M | 101.34M | 98.98M | 96.83M |
| Weighted Average Shares Outstanding Diluted | 120.45M | 120.73M | 120.07M | 119.39M | 118.57M | 117.73M | 116.71M | 115.62M | 114.76M | 114.11M | 113.57M | 112.97M | 111.90M | 110.87M | 109.87M | 108.71M | 107.39M | 101.34M | 98.98M | 96.83M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $344.07M | $359.28M | $219.75M | $587.45M | $663.60M |
| Short Term Investments | $49.34M | $29.41M | $210.24M | $- | $- |
| Cash and Short Term Investments | $393.40M | $388.69M | $429.98M | $587.45M | $663.60M |
| Net Receivables | $87.86M | $114.83M | $104.21M | $85.25M | $51.21M |
| Inventory | $83.11M | $73.71M | $81.63M | $59.97M | $29.96M |
| Other Current Assets | $20.02M | $18.79M | $19.21M | $28.82M | $42.62M |
| Total Current Assets | $584.39M | $596.02M | $635.03M | $747.59M | $774.37M |
| Property Plant Equipment Net | $309.94M | $344.93M | $359.21M | $230.41M | $119.82M |
| Goodwill | $4.51M | $4.51M | $4.51M | $4.51M | $- |
| Intangible Assets | $15.67M | $16.62M | $22.86M | $25.40M | $22.35M |
| Goodwill and Intangible Assets | $20.18M | $21.13M | $27.37M | $29.91M | $22.35M |
| Long Term Investments | $- | $- | $4.97M | $7.60M | $8.47M |
| Tax Assets | $- | $- | $-4.97M | $-7.60M | $-8.47M |
| Other Non-Current Assets | $4.13M | $3.06M | $7.37M | $10.92M | $12.80M |
| Total Non-Current Assets | $334.25M | $369.12M | $393.94M | $271.24M | $154.97M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $918.64M | $965.14M | $1.03B | $1.02B | $929.34M |
| Account Payables | $12.91M | $15.74M | $21.60M | $17.35M | $4.71M |
| Short Term Debt | $9.29M | $11.52M | $18.07M | $10.26M | $11.87M |
| Tax Payables | $4.94M | $5.05M | $4.08M | $4.62M | $8.65M |
| Deferred Revenue | $20.66M | $13.15M | $7.87M | $5.34M | $4.47M |
| Other Current Liabilities | $69.84M | $81.70M | $79.34M | $72.78M | $88.42M |
| Total Current Liabilities | $117.63M | $127.16M | $130.96M | $110.36M | $118.13M |
| Long Term Debt | $73.33M | $83.85M | $172.28M | $153.69M | $114.08M |
| Deferred Revenue Non-Current | $- | $8.81M | $3.17M | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-3.17M | $- | $- |
| Other Non-Current Liabilities | $17.54M | $4.28M | $-80.00M | $-62.79M | $-41.94M |
| Total Non-Current Liabilities | $90.87M | $96.94M | $92.28M | $90.90M | $72.14M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $208.50M | $224.10M | $223.24M | $201.26M | $190.27M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K |
| Retained Earnings | $-1.47B | $-1.28B | $-1.03B | $-863.32M | $-805.10M |
| Accumulated Other Comprehensive Income Loss | $-493.00K | $-429.00K | $-4.33M | $22.00K | $-50.00K |
| Other Total Stockholders Equity | $2.18B | $2.03B | $1.84B | $1.68B | $1.54B |
| Total Stockholders Equity | $710.13M | $741.04M | $805.74M | $817.57M | $739.07M |
| Total Equity | $710.13M | $741.04M | $805.74M | $817.57M | $739.07M |
| Total Liabilities and Stockholders Equity | $918.64M | $965.14M | $1.03B | $1.02B | $929.34M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $918.64M | $965.14M | $1.03B | $1.02B | $929.34M |
| Total Investments | $49.34M | $29.41M | $210.24M | $7.60M | $8.47M |
| Total Debt | $82.61M | $95.37M | $95.18M | $81.98M | $62.98M |
| Net Debt | $-261.45M | $-263.91M | $-124.57M | $-505.47M | $-600.62M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $344.07M | $398.16M | $379.82M | $355.78M | $359.28M | $311.26M | $325.88M | $332.32M | $219.75M | $233.95M | $274.19M | $312.49M | $587.45M | $600.44M | $621.96M | $617.20M | $663.60M | $768.77M | $339.84M | $372.43M |
| Short Term Investments | $49.34M | $- | $269.00K | $16.03M | $29.41M | $45.64M | $65.51M | $85.97M | $210.24M | $218.44M | $225.55M | $226.84M | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $393.40M | $398.16M | $380.09M | $371.81M | $388.69M | $356.91M | $391.38M | $418.29M | $429.98M | $452.39M | $499.73M | $539.32M | $587.45M | $600.44M | $621.96M | $617.20M | $663.60M | $768.77M | $339.84M | $372.43M |
| Net Receivables | $87.86M | $83.53M | $91.18M | $91.31M | $114.83M | $103.85M | $87.69M | $77.94M | $104.21M | $83.55M | $76.20M | $76.53M | $85.25M | $78.43M | $59.68M | $57.41M | $51.21M | $36.03M | $22.73M | $30.85M |
| Inventory | $83.11M | $94.05M | $88.27M | $83.19M | $73.71M | $80.92M | $83.69M | $82.31M | $81.63M | $78.63M | $70.65M | $63.70M | $59.97M | $51.14M | $44.09M | $38.51M | $29.96M | $25.12M | $21.76M | $19.36M |
| Other Current Assets | $20.02M | $18.16M | $19.61M | $20.79M | $18.79M | $20.68M | $20.18M | $23.36M | $19.21M | $14.86M | $19.65M | $35.55M | $14.92M | $14.09M | $31.45M | $32.61M | $29.60M | $70.53M | $67.26M | $14.19M |
| Total Current Assets | $584.39M | $593.89M | $579.15M | $567.09M | $596.02M | $562.35M | $582.94M | $601.89M | $635.03M | $629.42M | $666.23M | $697.34M | $747.59M | $744.10M | $757.17M | $745.72M | $774.37M | $900.45M | $451.58M | $429.73M |
| Property Plant Equipment Net | $309.94M | $318.34M | $324.16M | $332.34M | $344.93M | $354.20M | $355.96M | $366.84M | $359.21M | $328.79M | $296.43M | $265.88M | $230.41M | $203.30M | $176.45M | $163.67M | $119.82M | $110.49M | $99.07M | $96.43M |
| Goodwill | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $4.51M | $- | $- | $- | $- |
| Intangible Assets | $15.67M | $16.15M | $16.66M | $16.13M | $16.62M | $21.83M | $22.29M | $22.95M | $22.86M | $23.49M | $24.13M | $24.76M | $25.40M | $26.04M | $26.69M | $27.34M | $22.35M | $21.93M | $21.55M | $- |
| Goodwill and Intangible Assets | $20.18M | $20.66M | $21.17M | $20.64M | $21.13M | $26.34M | $26.80M | $27.46M | $27.37M | $28.00M | $28.64M | $29.27M | $29.91M | $4.51M | $4.51M | $4.51M | $22.35M | $21.93M | $21.55M | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $2.97M | $3.47M | $4.97M | $4.97M | $7.09M | $7.09M | $7.60M | $7.60M | $8.60M | $8.60M | $8.60M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $-2.97M | $-3.47M | $-4.97M | $-4.97M | $-7.09M | $-7.09M | $-7.60M | $-7.60M | $-8.60M | $-8.60M | $-8.60M | $- | $- | $- | $- |
| Other Non-Current Assets | $4.13M | $4.90M | $5.19M | $2.84M | $3.06M | $5.65M | $23.93M | $17.83M | $7.37M | $9.99M | $10.29M | $10.76M | $10.92M | $38.65M | $39.44M | $40.14M | $12.80M | $9.67M | $10.60M | $84.22M |
| Total Non-Current Assets | $334.25M | $343.90M | $350.51M | $355.82M | $369.12M | $386.19M | $406.70M | $412.14M | $393.94M | $366.79M | $335.36M | $305.92M | $271.24M | $246.47M | $220.41M | $208.32M | $154.97M | $142.09M | $131.22M | $180.65M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $918.64M | $937.79M | $929.67M | $922.91M | $965.14M | $948.54M | $989.64M | $1.01B | $1.03B | $996.21M | $1.00B | $1.00B | $1.02B | $990.57M | $977.58M | $954.03M | $929.34M | $1.04B | $582.80M | $610.38M |
| Account Payables | $12.91M | $26.21M | $21.25M | $20.22M | $15.74M | $18.84M | $23.12M | $29.32M | $21.60M | $21.59M | $26.73M | $18.96M | $17.35M | $17.04M | $16.18M | $15.58M | $4.71M | $9.49M | $9.92M | $13.51M |
| Short Term Debt | $9.29M | $18.83M | $21.64M | $11.13M | $23.04M | $20.01M | $18.57M | $18.40M | $9.04M | $16.79M | $15.95M | $15.27M | $5.13M | $8.93M | $9.81M | $12.31M | $5.94M | $9.95M | $7.88M | $6.91M |
| Tax Payables | $4.94M | $4.29M | $5.79M | $5.78M | $5.05M | $3.69M | $2.32M | $2.30M | $4.08M | $3.12M | $1.45M | $1.91M | $4.62M | $3.30M | $4.20M | $2.48M | $8.65M | $1.79M | $954.00K | $923.00K |
| Deferred Revenue | $20.66M | $17.76M | $16.44M | $14.30M | $13.15M | $11.14M | $9.22M | $8.53M | $7.87M | $6.67M | $6.47M | $5.43M | $5.34M | $5.50M | $5.27M | $4.48M | $4.47M | $3.77M | $3.43M | $3.39M |
| Other Current Liabilities | $69.84M | $54.14M | $45.90M | $57.32M | $70.18M | $51.03M | $44.85M | $53.46M | $88.38M | $78.69M | $67.31M | $52.88M | $77.91M | $65.61M | $77.66M | $85.70M | $94.36M | $120.57M | $100.00M | $34.34M |
| Total Current Liabilities | $117.63M | $121.23M | $111.02M | $108.73M | $127.16M | $104.72M | $98.09M | $112.01M | $130.96M | $126.86M | $117.91M | $94.45M | $110.36M | $100.38M | $113.13M | $120.55M | $118.13M | $145.57M | $122.18M | $59.07M |
| Long Term Debt | $73.33M | $76.46M | $78.66M | $81.05M | $167.70M | $176.94M | $180.66M | $185.69M | $86.14M | $175.67M | $182.08M | $187.08M | $76.85M | $151.47M | $131.83M | $66.34M | $57.04M | $113.24M | $110.46M | $112.33M |
| Deferred Revenue Non-Current | $12.51M | $12.35M | $11.36M | $9.79M | $8.81M | $- | $- | $- | $3.17M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-9.79M | $-1 | $- | $- | $- | $-3.17M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $5.03M | $4.95M | $4.57M | $4.51M | $-79.57M | $-78.33M | $-82.41M | $-86.05M | $6.14M | $-82.11M | $-81.91M | $-84.96M | $14.05M | $-61.49M | $-51.97M | $14.68M | $15.10M | $-41.34M | $-41.10M | $29.92M |
| Total Non-Current Liabilities | $90.87M | $93.75M | $94.59M | $95.35M | $96.94M | $98.61M | $98.25M | $99.64M | $92.28M | $93.56M | $100.17M | $102.12M | $90.90M | $89.98M | $79.87M | $81.02M | $72.14M | $71.89M | $69.35M | $142.25M |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $208.50M | $214.99M | $205.61M | $204.08M | $224.10M | $203.32M | $196.34M | $211.65M | $223.24M | $220.41M | $218.07M | $196.57M | $201.26M | $190.35M | $192.99M | $201.57M | $190.27M | $217.46M | $191.53M | $201.32M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K |
| Retained Earnings | $-1.47B | $-1.42B | $-1.38B | $-1.34B | $-1.28B | $-1.24B | $-1.14B | $-1.08B | $-1.03B | $-1.01B | $-970.19M | $-905.73M | $-863.32M | $-844.87M | $-827.70M | $-816.65M | $-805.10M | $-389.52M | $-323.68M | $-283.51M |
| Accumulated Other Comprehensive Income Loss | $-493.00K | $32.00K | $-430.00K | $-456.00K | $-429.00K | $-677.00K | $-969.00K | $-1.48M | $-4.33M | $-5.49M | $-3.96M | $-2.44M | $22.00K | $194.00K | $58.00K | $48.00K | $-50.00K | $-52.00K | $314.00K | $-41.00K |
| Other Total Stockholders Equity | $2.18B | $2.14B | $2.11B | $2.06B | $2.03B | $1.98B | $1.94B | $1.88B | $1.84B | $1.79B | $1.76B | $1.71B | $1.68B | $1.64B | $1.61B | $1.57B | $1.54B | $1.21B | $714.63M | $692.62M |
| Total Stockholders Equity | $710.13M | $722.80M | $724.06M | $718.83M | $741.04M | $745.22M | $793.30M | $802.38M | $805.74M | $775.79M | $783.52M | $806.68M | $817.57M | $800.22M | $784.59M | $752.46M | $739.07M | $825.08M | $391.27M | $409.07M |
| Total Equity | $710.13M | $722.80M | $724.06M | $718.83M | $741.04M | $745.22M | $793.30M | $802.38M | $805.74M | $775.79M | $783.52M | $806.68M | $817.57M | $800.22M | $784.59M | $752.46M | $739.07M | $825.08M | $391.27M | $409.07M |
| Total Liabilities and Stockholders Equity | $918.64M | $937.79M | $929.67M | $922.91M | $965.14M | $948.54M | $989.64M | $1.01B | $1.03B | $996.21M | $1.00B | $1.00B | $1.02B | $990.57M | $977.58M | $954.03M | $929.34M | $1.04B | $582.80M | $610.38M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $918.64M | $937.79M | $929.67M | $922.91M | $965.14M | $948.54M | $989.64M | $1.01B | $1.03B | $996.21M | $1.00B | $1.00B | $1.02B | $990.57M | $977.58M | $954.03M | $929.34M | $1.04B | $582.80M | $610.38M |
| Total Investments | $49.34M | $- | $269.00K | $16.03M | $29.41M | $45.64M | $65.51M | $85.97M | $210.24M | $218.44M | $225.55M | $226.84M | $7.60M | $8.60M | $8.60M | $8.60M | $- | $- | $- | $- |
| Total Debt | $82.61M | $85.88M | $89.48M | $92.18M | $95.37M | $98.47M | $99.62M | $102.04M | $95.18M | $96.23M | $99.02M | $101.17M | $81.98M | $80.20M | $70.82M | $72.50M | $62.98M | $61.59M | $59.17M | $59.62M |
| Net Debt | $-261.45M | $-312.28M | $-290.34M | $-263.61M | $-263.91M | $-212.79M | $-226.26M | $-230.28M | $-124.57M | $-137.72M | $-175.17M | $-211.31M | $-505.47M | $-520.24M | $-551.14M | $-544.70M | $-600.62M | $-707.18M | $-280.67M | $-312.81M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-182.63M | $-255.10M | $-166.00M | $-58.22M | $-542.73M |
| Depreciation and Amortization | $43.71M | $43.62M | $33.01M | $28.25M | $19.02M |
| Deferred Income Tax | $- | $- | $- | $- | $1.55M |
| Stock Based Compensation | $140.75M | $166.95M | $136.85M | $95.96M | $48.63M |
| Change in Working Capital | $1.25M | $17.34M | $-39.42M | $-87.44M | $-50.38M |
| Accounts Receivables | $26.95M | $-10.61M | $-18.95M | $-34.04M | $-17.85M |
| Inventory | $-9.78M | $7.87M | $-21.19M | $-30.13M | $-14.60M |
| Accounts Payables | $-3.35M | $-6.02M | $5.86M | $11.08M | $-7.77M |
| Other Working Capital | $-12.57M | $26.10M | $-5.13M | $-34.36M | $-10.16M |
| Other Non Cash Items | $3.58M | $11.99M | $1.96M | $79.00K | $306.02M |
| Net Cash Provided by Operating Activities | $6.66M | $-15.20M | $-33.61M | $-21.37M | $-217.90M |
| Investments in Property Plant and Equipment | $-12.39M | $-48.60M | $-131.66M | $-101.28M | $-38.39M |
| Acquisitions Net | $- | $- | $-4.00M | $-5.45M | $- |
| Purchases of Investments | $-48.88M | $- | $-282.87M | $- | $- |
| Sales Maturities of Investments | $29.64M | $183.02M | $67.64M | $- | $- |
| Other Investing Activities | $-1.00M | $-923.00K | $-215.23M | $- | $-1.73M |
| Net Cash Used for Investing Activities | $-32.63M | $133.49M | $-350.89M | $-106.73M | $-38.39M |
| Debt Repayment | $- | $- | $- | $- | $-37.10M |
| Common Stock Issued | $- | $19.48M | $21.23M | $40.33M | $482.27M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $10.91M | $13.67M | $15.82M | $35.30M | $23.74M |
| Net Cash Used Provided by Financing Activities | $10.91M | $13.67M | $15.82M | $35.30M | $468.91M |
| Effect of Forex Changes on Cash | $-164.00K | $-33.00K | $-44.00K | $234.00K | $-463.00K |
| Net Change in Cash | $-15.22M | $131.93M | $-368.72M | $-92.57M | $212.15M |
| Cash at End of Period | $344.07M | $359.28M | $227.35M | $596.07M | $688.64M |
| Cash at Beginning of Period | $359.28M | $227.35M | $596.07M | $688.64M | $476.49M |
| Operating Cash Flow | $6.66M | $-15.20M | $-33.61M | $-21.37M | $-217.90M |
| Capital Expenditure | $-12.39M | $-49.52M | $-131.66M | $-101.28M | $-38.39M |
| Free Cash Flow | $-5.73M | $-64.72M | $-165.27M | $-122.65M | $-256.29M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-49.03M | $-35.75M | $-37.90M | $-59.95M | $-48.95M | $-92.99M | $-62.41M | $-50.75M | $-17.21M | $-41.91M | $-64.46M | $-42.41M | $-18.45M | $-17.17M | $-11.05M | $-11.55M | $-415.57M | $-65.85M | $-40.17M | $-21.14M |
| Depreciation and Amortization | $10.56M | $10.75M | $10.90M | $11.49M | $11.71M | $11.42M | $11.88M | $8.62M | $8.47M | $8.12M | $8.44M | $7.97M | $7.32M | $7.28M | $7.19M | $6.47M | $5.42M | $4.88M | $4.47M | $4.26M |
| Deferred Income Tax | $- | $- | $- | $- | $23.85M | $-26.64M | $2.79M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.00K | $- | $- | $1.52M |
| Stock Based Compensation | $32.54M | $33.59M | $38.49M | $36.13M | $38.92M | $40.23M | $45.70M | $42.10M | $40.97M | $33.51M | $36.31M | $26.05M | $26.90M | $25.95M | $26.93M | $16.18M | $14.27M | $13.78M | $13.86M | $6.72M |
| Change in Working Capital | $-1.38M | $12.99M | $-4.07M | $-6.30M | $17.07M | $16.17M | $-9.93M | $-5.96M | $-19.34M | $-9.94M | $2.46M | $-12.59M | $-9.99M | $-42.27M | $-19.98M | $-15.21M | $-40.32M | $-8.44M | $-7.67M | $6.05M |
| Accounts Receivables | $-4.37M | $7.68M | $122.00K | $23.52M | $-10.97M | $-16.16M | $-9.75M | $26.28M | $-20.62M | $-7.35M | $297.00K | $8.73M | $-6.83M | $-19.39M | $-1.64M | $-6.19M | $-15.19M | $-13.30M | $8.12M | $2.52M |
| Inventory | $9.62M | $-4.26M | $-5.20M | $-9.94M | $7.61M | $2.57M | $-1.86M | $-449.00K | $-1.43M | $-8.66M | $-7.37M | $-3.74M | $-8.78M | $-7.13M | $-5.60M | $-8.61M | $-4.75M | $-3.36M | $-2.40M | $-4.09M |
| Accounts Payables | $-13.40M | $4.34M | $1.12M | $4.58M | $-3.21M | $-4.12M | $2.10M | $-781.00K | $-224.00K | $-4.18M | $7.39M | $2.88M | $-1.11M | $2.48M | $-1.17M | $10.88M | $-4.46M | $-497.00K | $-2.16M | $-653.00K |
| Other Working Capital | $6.77M | $5.23M | $-112.00K | $-24.46M | $23.63M | $33.89M | $-413.00K | $-31.01M | $2.93M | $10.25M | $2.14M | $-20.46M | $6.73M | $-18.22M | $-11.57M | $-11.29M | $-15.91M | $8.72M | $-11.24M | $8.27M |
| Other Non Cash Items | $552.00K | $64.00K | $64.31M | $43.85M | $-16.83M | $26.50M | $463.00K | $1.86M | $837.00K | $660.00K | $277.00K | $183.00K | $13.00K | $64.55M | $36.00K | $30.00K | $306.00M | $-1.00K | $1.00K | $17.00K |
| Net Cash Provided by Operating Activities | $-6.75M | $21.64M | $7.50M | $-15.72M | $25.76M | $-25.30M | $-11.53M | $-4.12M | $13.72M | $-9.56M | $-16.96M | $-20.80M | $5.80M | $-26.22M | $3.12M | $-4.08M | $-130.18M | $-55.63M | $-29.52M | $-2.58M |
| Investments in Property Plant and Equipment | $-2.72M | $-3.89M | $-3.88M | $-2.91M | $-3.45M | $-15.44M | $-25.36M | $-5.28M | $-39.73M | $-36.57M | $-27.22M | $-28.14M | $-27.62M | $-20.23M | $-14.57M | $-38.87M | $-22.27M | $-1.31M | $-6.74M | $-8.08M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $-2.50M | $-1.50M | $1.50M | $1.50M | $- | $- | $- | $-5.45M | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $-1.50M | $-11.32M | $-29.22M | $-242.33M | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $271.00K | $15.82M | $13.54M | $16.55M | $20.34M | $20.89M | $125.24M | $9.06M | $16.77M | $28.91M | $12.91M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-48.88M | $- | $-1.00M | $13.54M | $1 | $20.14M | $20.89M | $124.52M | $1.50M | $5.44M | $-1.50M | $-1.50M | $- | $- | $- | $- | $-927.00K | $-801.00K | $- | $- |
| Net Cash Used for Investing Activities | $-51.59M | $-3.62M | $11.95M | $10.63M | $13.10M | $4.90M | $-4.46M | $119.96M | $-33.17M | $-32.63M | $-27.53M | $-257.56M | $-27.62M | $-20.23M | $-14.57M | $-44.32M | $-22.27M | $-1.31M | $-6.74M | $-8.08M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $5.85M | $- | $- | $-31.26M |
| Common Stock Issued | $- | $-6.24M | $4.60M | $1.64M | $5.61M | $4.37M | $7.10M | $2.40M | $21.23M | $2.04M | $6.36M | $7.83M | $40.33M | $6.68M | $16.19M | $8.55M | $-780.00K | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $4.52M | $156.00K | $4.60M | $1.64M | $5.61M | $4.37M | $7.10M | $-5.81M | $5.00M | $2.04M | $6.36M | $2.42M | $8.90M | $6.68M | $16.19M | $3.52M | $2.64M | $486.97M | $8.05M | $-2.56M |
| Net Cash Used Provided by Financing Activities | $4.52M | $156.00K | $4.60M | $1.64M | $5.61M | $4.37M | $7.10M | $-3.41M | $5.00M | $2.04M | $6.36M | $2.42M | $8.90M | $6.68M | $16.19M | $3.52M | $7.71M | $486.97M | $8.05M | $-33.82M |
| Effect of Forex Changes on Cash | $-269.00K | $156.00K | $-3.00K | $-48.00K | $77.00K | $-85.00K | $-49.00K | $24.00K | $251.00K | $-85.00K | $-192.00K | $-18.00K | $-82.00K | $117.00K | $6.00K | $193.00K | $-319.00K | $-21.00K | $-7.00K | $-116.00K |
| Net Change in Cash | $-54.09M | $18.34M | $24.04M | $-3.50M | $47.52M | $-15.62M | $-8.94M | $112.44M | $-14.20M | $-40.24M | $-38.32M | $-275.96M | $-12.99M | $-39.64M | $4.75M | $-44.69M | $-145.05M | $430.01M | $-28.21M | $-44.59M |
| Cash at End of Period | $344.07M | $398.16M | $379.82M | $355.78M | $359.28M | $311.76M | $330.85M | $339.79M | $227.35M | $241.55M | $281.79M | $320.11M | $596.07M | $609.07M | $648.71M | $643.96M | $688.64M | $833.70M | $403.69M | $431.90M |
| Cash at Beginning of Period | $398.16M | $379.82M | $355.78M | $359.28M | $311.76M | $327.38M | $339.79M | $227.35M | $241.55M | $281.79M | $320.11M | $596.07M | $609.07M | $648.71M | $643.96M | $688.64M | $833.70M | $403.69M | $431.90M | $476.49M |
| Operating Cash Flow | $-6.75M | $21.64M | $7.50M | $-15.72M | $25.76M | $-25.30M | $-11.53M | $-4.12M | $13.72M | $-9.56M | $-16.96M | $-20.80M | $5.80M | $-26.22M | $3.12M | $-4.08M | $-130.18M | $-55.63M | $-29.52M | $-2.58M |
| Capital Expenditure | $-2.72M | $-3.89M | $-3.88M | $-2.91M | $-3.45M | $-15.44M | $-25.36M | $-5.28M | $-39.73M | $-36.57M | $-27.22M | $-28.14M | $-27.62M | $-20.23M | $-14.57M | $-38.87M | $-22.27M | $-1.31M | $-6.74M | $-8.08M |
| Free Cash Flow | $-9.46M | $17.75M | $3.62M | $-18.64M | $22.31M | $-40.74M | $-36.88M | $-9.41M | $-26.01M | $-46.14M | $-44.18M | $-48.94M | $-21.81M | $-46.44M | $-11.45M | $-42.95M | $-152.44M | $-56.94M | $-36.26M | $-10.65M |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
$8.38
Stock Price
$1.03B
Market Cap
1.31K
Employees
Pleasanton, CA
Location
Revenue (FY 2024)
$610.78M
-1.3% YoY
Net Income (FY 2024)
$-182.63M
28.4% YoY
EPS (FY 2024)
$-1.52
30.3% YoY
Free Cash Flow (FY 2024)
$-5.73M
91.1% YoY
Profitability
Gross Margin
67.9%
Net Margin
-29.9%
ROE
-25.7%
ROA
-19.9%
Valuation
P/E Ratio
-9.47
P/S Ratio
2.83
EV/EBITDA
-10.96
Market Cap
$1.03B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$6.66M
143.9% YoY
Free Cash Flow
$-5.73M
91.1% YoY
Balance Sheet Summary
Total Assets
$918.64M
-4.8% YoY
Total Debt
$82.61M
13.4% YoY
Shareholder Equity
$710.13M
-6.8% YoY
Dividend Overview
No Dividend Data
10x Genomics, Inc. doesn't currently pay dividends.
10x Genomics Dividends
Explore 10x Genomics's dividend history, including dividend yield, payout ratio, and historical payments.
10x Genomics News
Read the latest news about 10x Genomics, including recent articles, headlines, and updates.
Torex Gold Reports Q1 2025 Production Results
Processing plant tie-ins concluded and first copper concentrate achieved; quarterly production in line with plan (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports Q1 2025 gold equivalent ("AuEq") payable production of 59,630 ounces ("oz") and AuEq sold of 60,568 oz. The Company is on track to achieve annual payable production guidance of 400,000 to 450,000 oz AuEq1.
Vizgen Announces End of Litigation with 10x Genomics and Harvard University
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #neuroscience--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an open letter in response to the settlement of litigation between Vizgen, Harvard University and 10X Genomics in the United States District Court for the District of Delaware. Dear Customers, Researchers and Friends of Vizgen: On February 5th, we secured an important settlement putting an end to litigation, including.
Torex Gold Reports First Copper Concentrate Production from Media Luna
Processing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces completion of the four-week tie-in period for the Media Luna Project ("Media Luna") and first production of precious metal-rich copper concentrate. Jody Kuzenko, President and CEO of Torex, stated: "Following almost three years to the day of the release of our feasibility study for the Media Luna Project, we have completed the tie-in period at our processing plant and achieved first production of copper concentrate.
10x Genomics: Lower Cost Innovation May Drive A Rebound
I assign TXG a buy rating with a 1-year price target of $12.7 per share, projecting an 18% upside YoY. TXG's new lower-cost Chromium offerings could drive volume growth and increased adoption, particularly in the biopharma sector, presenting significant revenue opportunities. Despite historical underperformance and high risk, TXG's leading technologies and potential market penetration justify holding the stock at current price levels.
Torex Gold Reports Year-End 2024 Reserves & Resources
Drilling success continues to support reserve life extensions (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to report year-end 2024 mineral reserves and resources for the Morelos Complex, which includes the producing El Limón Guajes ("ELG") Mine Complex (consisting of the ELG Open Pits and ELG Underground), Media Luna Underground mine, development phase EPO Underground deposit, and surface stockpiles. Table 1: Year-over-year comparison of mineral reserves & mineral resources for the Morelos Complex December 31, 2024 December 31, 2023 Variance Tonnes AuEq AuEq Tonnes AuEq AuEq Tonnes AuEq AuEq (kt) (gpt) (koz) (kt) (gpt) (koz) (kt) (gpt) (koz) Proven & Probable Reserves Media Luna Underground 24,180 4.26 3,311 23,569 4.43 3,360 3% (4%) (1%) ELG Underground 4,019 5.12 662 3,504 5.81 654 15% (12%) 1% EPO Underground 5,029 4.83 781 - - - na na na ELG Open Pit 945 2.69 82 5,553 3.16 565 (83%) (15%) (86%) Surface Stockpiles 6,235 1.30 261 4,972 1.20 192 25% 8% 36% Total Morelos Complex 40,408 3.92 5,096 37,598 3.95 4,771 7% (1%) 7% Measured & Indicated Resources Media Luna Underground 29,114 5.07 4,744 27,451 5.23 4,618 6% (3%) 3% ELG Underground 8,451 5.20 1,414 8,176 5.48 1,441 3% (5%) (2%) EPO Underground 7,060 5.18 1,176 6,979 5.14 1,153 1% 1% 2% ELG Open Pit 1,054 2.86 97 6,110 3.13 615 (83%) (9%) (84%) Total Morelos Complex 45,679 5.06 7,431 48,717 5.00 7,828 (6%) 1% (5%) Inferred Resources Media Luna Underground 7,675 4.12 1,017 7,330 4.25 1,001 5% (3%) 2% ELG Underground 1,961 4.30 271 2,396 5.28 407 (18%) (19%) (33%) EPO Underground 6,883 4.31 954 4,960 4.52 721 39% (5%) 32% ELG Open Pit 6 3.65 1 399 2.08 27 (98%) 75% (97%) Total Morelos Complex 16,526 4.22 2,243 15,085 4.45 2,156 10% (5%) 4% Notes to Table: 1.
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif. , March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
Torex Gold Reports Excellent Drill Results from Media Luna West and Initial Results from Media Luna East
Compelling results return multiple high-grade intercepts at both Media Luna East and West (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 24, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide results from the ongoing drilling program at Media Luna West and results from initial drill testing at Media Luna East. Drilling at both targets supports the Company's exploration strategy, which is focused, in part, on unlocking additional near-mine opportunities at the Media Luna Cluster in order to further enhance and extend the production profile of the Morelos Complex.
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis
New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif. , Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale.
Torex Gold Reports Q4 and Full Year 2024 Results
2024 marks another solid year of operational and financial results; on track to return to positive free cash flow generation by mid-2025 (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 19, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three months and year ended December 31, 2024. Torex will host a conference call tomorrow morning at 9:00 AM (ET) to discuss the results.
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
PLEASANTON, Calif. , Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, at 11:10 a.m.
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
10x Genomics, Inc. (NASDAQ:TXG ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Cassie Corneau - Senior Director, IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Adam Taich - CFO Conference Call Participants Dan Brennan - TD Cowen Patrick Donnelly - Citi Dan Arias - Stifel Puneet Souda - Leerink Partners Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Tejas Savant - Morgan Stanley Dan Leonard - UBS Subbu Nambi - Guggenheim Securities Kyle Mikson - Canaccord Genuity Luke Sergott - Barclays Matt Larew - William Blair Matt Sykes - Goldman Sachs Michael Ryskin - Bank of America Operator Thank you for standing by. My name is [Prilla] and I will be your conference operator today.
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
The headline numbers for 10x Genomics (TXG) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
PLEASANTON, Calif. , Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for 10x Genomics (TXG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Chan Zuckerberg Initiative Launches Billion Cells Project with 10x Genomics and Ultima Genomics to Advance AI in Biology
Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology.
Torex Gold Provides Q4 2024 Update on Media Luna Project
Construction substantially complete and first copper concentrate on track for March (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides a Q4 2024 update on the development of its Media Luna Project ("Media Luna"). Unless otherwise stated, progress and milestones referenced in this press release are as of December 31, 2024.
Spatial Omics Research Report 2023-2034: Market to reach $1.09 Billion - 10x Genomics Enhances Spatial OMICS with New Visium Spatial Gene Expression for FFPE
Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Spatial Omics Market by Technology, by Product, by Workflow, by Sample Type, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering. The global spatial OMICS market accounted for USD 0.372 billion in 2023 and is expected to reach USD 1.09 billion by 2034 with a CAGR of 10.27% during the forecast period 2024-2034
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025
PLEASANTON, Calif. , Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025.
Torex Gold Provides 2025 Operational Guidance and Updated Five-Year Production Outlook
On track to return to positive free cash flow mid-year as Media Luna ramps up (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - January 14, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) provides 2025 operational guidance as well as an updated five-year production outlook for the Morelos Complex. Full-year guidance assumes a four-week shutdown of the processing plant during the first quarter to carry out upgrades and tie-ins required to complete the Media Luna Project.
Torex Gold Delivers on Full-Year Production Guidance
2024 marks the sixth consecutive year production guidance has been achieved Toronto, Ontario--(Newsfile Corp. - January 8, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports fourth quarter gold production of 103,795 ounces ("oz") and full-year gold production of 452,523 oz, within the Company's revised guidance range of 450,000 to 470,000 oz (original guidance of 400,000 to 450,000 oz). Fourth quarter and full-year gold sold were 108,647 oz and 455,932 oz, respectively.
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products
PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies.
Torex Gold to Restart Operations and Project Activities at the Morelos Complex
Toronto, Ontario--(Newsfile Corp. - December 17, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Director General of Mines under the Federal Ministry of Economy has lifted the temporary suspension notice and allowed for all activities within the Morelos Complex to resume. Jody Kuzenko, President & CEO of Torex, stated: "Following notification that the temporary suspension has been lifted by the Director General of Mines, all production and development activities at the Morelos Complex will resume, including open pit and underground mining, processing operations, and all activities associated with the Media Luna Project.
Torex Gold Receives Notice of Temporary Suspension from the Ministry of Economy
Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Company has received a notification from the Director General of Mines under the Federal Ministry of Economy that all activities within the Morelos Property are to be temporarily suspended to support their inspection associated with the fatal incident at the El Limón Guajes underground mine ("ELG Underground") on December 5th. As a result, all operational and project activities within the Morelos Complex have been temporarily halted pending permission from officials to resume activities.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for TXG.